Department: Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE)

Phone: +34 966 658 727

Email: aferrer@umh.es

ResearchGate: Antonio Ferrer Montiel

Current Position: Director of the Instituto de Biología Molecular y Celular (IBMC), Universidad Miguel Hernández.

​

Research Fields

• Molecular dermatology: sensitive skin pathophysiology.

• Chronic Pain mechanisms.

• Pain and pruritus therapeutics.

Representative Publications

• Nikolaeva-Koleva M, Butron L, González-Rodríguez S, Devesa I, Valente P, Serafini M, Genazzani AA, Pirali T, Ballester GF, Fernández-Carvajal A, Ferrer-Montiel A. A capsaicinoid-based soft drug, AG1529, for attenuating TRPV1-mediated histaminergic and inflammatory sensory neuron excitability. Sci Rep. 2021 Jan 8;11(1):246. doi: 10.1038/s41598-020-80725-z.

​

• Fernández-Carvajal A, González-Muñiz R, Fernández-Ballester G, Ferrer-Montiel A.  Investigational drugs in early phase clinical trials targeting thermotransient receptor potential (thermoTRP) channels. Expert Opin Investig Drugs. 2020 Sep 29:1-14. doi: 10.1080/13543784.2020.1825680.

​

• Artero-Morales M, González-Rodríguez S, Ferrer-Montiel A.TRP Channels as Potential Targets for Sex-Related Differences in Migraine Pain. Front Mol Biosci. 2018 Aug 14;5:73. doi: 10.3389/fmolb.2018.00073. eCollection 2018. 

​

• Serafini M, Griglio A, Aprile S, Seiti F, Travelli C, Pattarino F, Grosa G, Sorba G, Genazzani AA, Gonzalez Rodriguez S, Butron L, Devesa I, Fernandez-Carvajal A, Pirali T, Ferrer-Montiel A.Targeting Transient Receptor Potential Vanilloid 1 (TRPV1) Channel Softly: The Discovery of Passerini Adducts as a Topical Treatment for Inflammatory Skin Disorders. JMed Chem. 2018 May 24;61(10):4436-4455. doi: 10.1021/acs.jmedchem.8b00109.

​

• Ciardo MG, Andrés-Bordería A, Cuesta N, Valente P, Camprubí-Robles M, Yang J, Planells-Cases R, Ferrer-Montiel A. Whirlin increases TRPV1 channel expression and cellular stability. Biochimica et Biophysica Acta. (2016) Jan;1863(1):115-27. doi: 10.1016/j.bbamcr.2015.10.016.

​​

• Mathivanan S, Devesa I, Changeux JP, Ferrer-Montiel A. Bradykinin Induces TRPV1 Exocytotic Recruitment in Peptidergic Nociceptors. Frontiers in Pharmacology (2016) Jun 23;7:178. doi: 10.3389/fphar.2016.00178. eCollection 2016 Jun 23.

​​

• Devesa I, Wolf C, Mathivanan S, Ferrandiz-Huertas C, Lujan R, Changeux J.-P. and Ferrer-Montiel A. α-CGRP is essential for pro-algesic sensitization of TRPV1 in peptidergic C-type nociceptors. Proceedings of the National Academy of Sciences of the U.S.A. (2014) 111, 18345-18350.

​​​

Patents and Available Technologies

• Blanes C, Llobregat M, Gil A, Fernández-Ballester G, Planells Cases R, Viniegra S, Gutierrez LM, Carbonell T, Pérez-Payá E, Ferrer-Montiel. A. Neuronal exocytosis inhibiting peptide and cosmetic composition and pharmaceutical composition containing the peptide. US77473679 B1 (granted on 21/03/2006).  Producto cosmeceutico Argireline®, explotado por LIPOTEC SAU.

​​

• Cristina Carreño, Berta Ponsati, Wim Van Den Nest, Jimena Fernández, María Camprubí Robles, Antonio Ferrer‑Montiel. Compositions for the treatment of pain and/or inflammation. WO2010/009892 A2. Producto DD04107. Desarrollo clínico por BCN Peptides.

​​

• Antonio Ferrer‑Montiel, Asia Fernández-Carvajal, Carlos Belmonte Martínez, Félix Viana, Juana Gallar, Pharmaceutical composition for the treatment of dry eye. WO2012/032209 A3. Formulación producto WS-12. Desarrollo clínico AvizoRx.

​​

• Antonio Ferrer Montiel, Gregorio Fernández Ballester, José María García Antón, Cristina Carreño,Núria Almiñana, Raquel Delgado. Compounds which inhibit neuronal exocytosis. WO2013153196 (A1). Desarrollo cosmecéutico L´OREAL.

​​

• Antonio Ferrer Montiel, A. Fernández-Carvajal, R. de la Torre, M.A. Juana Gallar, Carlos Belmonte, Gian Cesare Tron, Valentina Mercali, Armando Genazzani. Compuestos agonistas del receptor trpm8 y sus aplicaciones, UMH. PCT/ES2017/070026

​​

• Antonio Ferrer Montiel, A. Fernández-Carvajal, Isabel Devesa, Tracey Pirali, Armando Genazzani. TRPV1 modulator compounds. AntalGenics SL. EP17382266

Company Agreements

• AntalGenics

• BCN Peptides

• Prospera Biotech

Spin-off companies

• Fastbase Solutions (2015-present)

• AntalGenics (2015-present)

• Prospera Biotech (2014-present)

• Diverdrugs (1999-2012)